De Alba MAG, Sánchez MLC

Language: Spanish
References: 9
Page: 73-78
PDF size: 51.24 Kb.

ABSTRACT

Objetives: To demonstrate that the immediate dose scheme (24-48 h) after the TURB (Transuretral Resection of the Bladder) diminishes the rate of recurrence and tumor progression, compared with the mediate dose post TURB; thus allowing to diminish the collateral effects and to finish the schemes in the greater number of patients. Within the specific objectives one is to identify the group of age; which has the greater incidence of superficial bladder cancer in our Hospital, to analyze the most common types of recurrence and to identify the more common adverse effects and their characteristics. Material and methods: Prospective longitudinal study in which the patients with superficial bladder cancer (Ta, T1) seeing in the UMAE Especialidades “La Raza” are included; with confirming histopathology diagnosis, with or without previous TURB; having not received chemotherapy nor radiotherapy previously. The patients with invading cancer are excluded, also patients with history of other neoplasias, refractory urinary infection and the patients who did not tolerate the intravesical epirubicine for more than 90 minutes or presented severe adverse reactions (hematuria or dysuria). Patiens were distributed in random fashion for the application of the immediate epirubicine scheme or the mediate (traditional) scheme of 6 weekly doses and 6 monthly. Results: 16 patients with superficial bladder cancer were included and distributed in random form for application of epirubicine: Immediate scheme versus mediate. 3 patients were eliminated because they could not tolerate the medicine, severe hematuria or disuria. 2 patients were excluded: One because of advanced cancer and the other because the aplication of chemotherapy. The immediate scheme was applied to 8 patients and the mediate to 6; there were not significant differences between the age’s groups, or the stage of the tumor; neither in the secondary effects; the intolerance to the treatment appeared in 12.5% of the patients of the immediate scheme and 33% of mediate. The early recurrence appeared in 12.5% of the immediate group and 33% of the mediate one (‹ of 0,346 with p ‹ 0.05). The diagnosis was made by means of cistoscopy. Conclusions: The scheme for the application of the epirubicine in the first 24 to 48 hours after the TURB was modified; the obtained results allowed us to corroborate that the index of early recurrence (3 to 6 months) is smaller with the immediate scheme versus the mediate one; and allows a better tolerance until the term of the protocol. The secondary reactions are solely local and can be handled with symptomatic; not appearing any hematology alteration characteristic of the systemic chemotherapy.

REFERENCES

1. Hirofumi K, Kentaro K, et. al. A randomized controlled trial of shortterm versus long-term prophilactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 2003; 170: 433-7.

2. Fadi N, Brian S, et al. Contemporary management of superficial bladder cancer in the United States: A pattern of care analysis. Urol; 62(6): 1083-8.

3. Clifford Y, Scott M, et al. Urinary Bladder Cancer. Clin Obst & Gyn 2002; 45(3): 844-54.

4. Pashos C, Botteman M, et al. Bladder Cancer: Epidemiology. Diagnosis, and Management. Cancer Pract 2003; 10(6): 311-22.

5. AUA Annual Meeting. The Treatment of Bladder Cancer- Stage by Stage; 2000.

6. Kazuo G, Masashi N. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urol ; 53(2): 308-14.

7. Masters JR, Popert R. Intravesical chemotherapy with epirubicin: A dose response study. 1999; 16(5): 1490-3.

8. Ali-El-Dein B, El-Baz M, et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (Stages pTa and pT1): A randomized prospective study. J Urol 1997; 158(1): 68-73.

9. Ali-El-Dein, Nave A, et al. Sequential bacillus Calmette- Guerin an Epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: A randomized prospective study. 1999; 162(2): 339-42.